Literature DB >> 24018920

Obtaining blood cultures by venipuncture versus from central lines: impact on blood culture contamination rates and potential effect on central line-associated bloodstream infection reporting.

John M Boyce1, Jacqueline Nadeau, Diane Dumigan, Debra Miller, Cindy Dubowsky, Lenore Reilly, Carla V Hannon.   

Abstract

OBJECTIVE: Reduce the frequency of contaminated blood cultures that meet National Healthcare Safety Network definitions for a central line-associated bloodstream infection (CLABSI).
DESIGN: An observational study.
SETTING: A 500-bed university-affiliated hospital.
METHODS: A new blood culture policy discouraged drawing blood samples from central lines. Phlebotomists were reeducated regarding aseptic technique when obtaining blood samples by venipuncture. The intravenous therapy team was taught how to draw blood samples by venipuncture and served as a backup when phlebotomists were unable to obtain blood samples. A 2-nurse protocol and a special supply kit for obtaining blood samples from catheters were developed. Rates of blood culture contamination were monitored by the microbiology laboratory.
RESULTS: The proportion of blood samples obtained for culture from central lines decreased from 10.9% during January-June 2010 to 0.4% during July-December 2012 (P < .001). The proportion of blood cultures that were contaminated decreased from 84 (1.6%) of 5,274 during January-June 2010 to 21 (0.5%) of 4,245 during January-June 2012 (P < .001). Based on estimated excess hospital costs of $3,000 per contaminated blood culture, the reduction in blood culture contaminants yielded an estimated annualized savings of $378,000 in 2012 when compared to 2010. In mid-2010, 3 (30%) of 10 reported CLABSIs were suspected to represent blood culture contamination compared with none of 6 CLABSIs reported from mid-November 2010 through June 2012 (P = 0.25).
CONCLUSIONS: Multiple interventions resulted in a reduction in blood culture contamination rates and substantial cost savings to the hospital, and they may have reduced the number of reportable CLABSIs.

Mesh:

Year:  2013        PMID: 24018920     DOI: 10.1086/673142

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  10 in total

1.  Molecular diagnosis of sepsis: New aspects and recent developments.

Authors:  O Liesenfeld; L Lehman; K-P Hunfeld; G Kost
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

Review 2.  Practical Guidance for Clinical Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem

Authors:  Gary V Doern; Karen C Carroll; Daniel J Diekema; Kevin W Garey; Mark E Rupp; Melvin P Weinstein; Daniel J Sexton
Journal:  Clin Microbiol Rev       Date:  2019-10-30       Impact factor: 26.132

3.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

4.  Culture Ordering for Patients with New-onset Fever: A Survey of Pediatric Intensive Care Unit Clinician Practices.

Authors:  Lauren D Booth; Anna C Sick-Samuels; Aaron M Milstone; James C Fackler; Lindsey K Gnazzo; David C Stockwell
Journal:  Pediatr Qual Saf       Date:  2021-08-26

Review 5.  Blood Culture Utilization in the Hospital Setting: a Call for Diagnostic Stewardship.

Authors:  Valeria Fabre; Karen C Carroll; Sara E Cosgrove
Journal:  J Clin Microbiol       Date:  2021-07-14       Impact factor: 11.677

Review 6.  How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art.

Authors:  Brigitte Lamy; Sylvie Dargère; Maiken C Arendrup; Jean-Jacques Parienti; Pierre Tattevin
Journal:  Front Microbiol       Date:  2016-05-12       Impact factor: 5.640

7.  Trainee-led Engagement of the Care Team Improves Application of an Institutional Blood Culture Clinical Decision Algorithm to Pediatric Oncology Inpatients: A Single-institution Quality Improvement Project.

Authors:  Kathryn M Lemberg; Danielle W Koontz; David J Young; P Galen DiDomizio; Anne King; Allen R Chen; Christopher J Gamper; Elizabeth Colantuoni; Aaron M Milstone; Stacy L Cooper
Journal:  Pediatr Qual Saf       Date:  2022-03-30

8.  Initial Specimen Diversion Device Utilization Mitigates Blood Culture Contamination Across Regional Community Hospital and Acute Care Facility.

Authors:  Mark D Povroznik
Journal:  Am J Med Qual       Date:  2022-03-30       Impact factor: 1.200

9.  Reduction in Blood Culture Contamination Through Use of Initial Specimen Diversion Device.

Authors:  Mark E Rupp; R Jennifer Cavalieri; Cole Marolf; Elizabeth Lyden
Journal:  Clin Infect Dis       Date:  2017-07-15       Impact factor: 9.079

10.  Diagnostic Stewardship for Healthcare-Associated Infections: Opportunities and Challenges to Safely Reduce Test Use.

Authors:  Gregory R Madden; Robert A Weinstein; Costi D Sifri
Journal:  Infect Control Hosp Epidemiol       Date:  2018-01-14       Impact factor: 3.254

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.